Astellas Pharma Inc. · TSE:4503
Astellas Pharma — Q1 2018 Earnings Presentation
5 slides from Astellas Pharma's earnings presentation, July 2018
Slide 1: R&D Pipeline (As of Jul 2018) - Oncology (1/2)
R&D Pipeline (As of Jul 2018) Underlined items indicate changes from the previous announcement on Apr 26, 2018. Oncology (1/2) *Compounds with "In-house" in this column include ones discovered by collaborative research. Code No. Dosage Generic Name Classification Target Disease Phase / Area Licensor
Slide 2: Oncology (2/2)
Oncology (2/2) *Compounds with "In-house" in this column include ones discovered by collaborative research. Code No. Dosage Generic Name Classification Target Disease Phase / Area Licensor* Focus Area approach Form (Brand Name) AGS62P1 Acute myeloid leukemia P-I Injection In-house (ADC technology, E
Slide 3: Immunology, Muscle disease and Ophthalmology
Immunology, Muscle disease and Ophthalmology *Compounds with "In-house" in this column include ones discovered by collaborative research. Code No. Dosage Generic Name Classification Target Disease Phase / Area Licensor* Focus Area approach Form (Brand Name) FK506 Immunosuppressant Prevention of reje
Slide 4: Urology and Nephrology
Urology and Nephrology *Compounds with "In-house" in this column include ones discovered by collaborative research. Code No. Dosage Generic Name Classification Target Disease Phase / Area Licensor* Focus Area Approach Form (Brand Name) EB178 Combination therapy of solifenacin Overactive bladder with
Slide 5: Others
Others *Compounds with "In-house" in this column include ones discovered by collaborative research. Code No. Dosage Generic Name Classification Target Disease Phase / Area Licensor* Focus Area approach Form (Brand Name) fidaxomicin Macrocyclic antibiotic Infectious enteritis Approved (Jul. 2018) / J